Gregory Weaver
2019 - Sevion Therapeutics
In 2019, Gregory Weaver earned a total compensation of $1.2M as Chief Financial Officer at Sevion Therapeutics, a 125% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $71,760 |
|---|---|
| Option Awards | $470,400 |
| Salary | $357,650 |
| Stock Awards | $230,600 |
| Other | $46,466 |
| Total | $1,176,876 |
Weaver received $470.4K in option awards, accounting for 40% of the total pay in 2019.
Weaver also received $71.8K in non-equity incentive plan, $357.7K in salary, $230.6K in stock awards and $46.5K in other compensation.
Rankings
In 2019, Gregory Weaver's compensation ranked 8,522nd out of 13,971 executives tracked by ExecPay. In other words, Weaver earned more than 39.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,522 out of 13,971 | 39th |
Division Manufacturing | 3,380 out of 5,701 | 41st |
Major group Chemicals And Allied Products | 1,282 out of 2,200 | 42nd |
Industry group Drugs | 1,091 out of 1,886 | 42nd |
Industry Biological Products, Except Diagnostic Substances | 245 out of 389 | 37th |
Source: SEC filing on April 1, 2020.
Weaver's colleagues
We found three more compensation records of executives who worked with Gregory Weaver at Sevion Therapeutics in 2019.